{"cursor":"3029","size":15,"audio":[],"currentlang":"en","article":"{{Infobox company|\n| company_name = Exelixis company_logo = company_type = Public company traded_as\n| = company_slogan = A Better Way to Better Medicine| foundation = 1994 location\n| = South San Francisco, California, USA key_people = Michael Morrissey,\n| President, Research and Development Frank Karbe, CFO Gisela M. Schwab,\n| Executive Vice President and Chief Medical Officer Pamela A. Simonton,\n| Executive Vice President and General Counsel Peter Lamb, Senior Vice\n| President, Discovery Research and Chief Scientific Officer Lupe M. Rivera,\n| Senior Vice President, Operations industry = Biotechnology homepage =\n| [http://www.exelixis.com/ www.exelixis.com]\n}}\n\n'Exelixis' is a genomics-based drug discovery company located in South San\nFrancisco, Ca., and the producer of Cometriq, a treatment approved by the U.S.\nFood and Drug Administration (FDA) for medullary thyroid cancer with clinical\nactivity in several other types of metastatic cancer. It works on the\ndevelopment of anti-cancer therapies. Exelixis has several compounds in various\nstages of FDA approval including :\n* XL147 that targets phosphoinositide-3 kinase (PI3K); and\n* XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway.\n* XL880 (foretinib)\n\nThe company also has various compounds in phase 1 clinical trials, including\n* XL518 or GDC0973, a small molecule inhibitor of the MEK. Co-developed\n  with Roche.\n* XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a\n  range of human tumors;\n* XL139 that targets Hedgehog; XL413, a small molecule inhibitor of the serine-\n  threonine kinase CDC7;\n* XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the\n  activity and stability of a range of regulatory proteins, including kinases. http://seekingalpha.com/article/270085-exelixis-looming-cancer-\n  conference-a-favorable-swing-trade-opportunity\n\nIts lead compound, XL184, has been approved for treatment of medullary thyroid\ncancer and is currently in a number of clinical trials for prostate, ovarian,\nbrain, melanoma, breast, non-small cell lung, hepatocellular, kidney. During its\ntrial for the treatment of medullary thyroid cancer, XL184 was designated orphan\ndrug status by the FDA and given the generic name, cabozantinib. Cabozantinib is\nan inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to\nabrogate tumor growth, metastasis, and angiogenesis.\n","linknr":130,"url":"Exelixis","recorded":1376418696,"links":["/w/index.php?title=Exelixis&action=edit","/w/index.php?title=Exelixis&action=edit","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","http://en.wikipedia.org/wiki/Exelixis","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.visualEditor.viewPageTarget.noscript&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","#mw-navigation","#p-search","/wiki/File:Exilixis_logo.PNG","//upload.wikimedia.org/wikipedia/en/thumb/1/19/Exilixis_logo.PNG/220px-Exilixis_logo.PNG","/wiki/Types_of_business_entity","/wiki/Public_company","/wiki/Ticker_symbol","/wiki/NASDAQ","http://www.nasdaq.com/symbol/exel","/wiki/Biotechnology","/wiki/South_San_Francisco,_California","/wiki/USA","http://www.exelixis.com/","/wiki/Genomics","/wiki/Cometriq","/wiki/Food_and_Drug_Administration","/wiki/Medullary_thyroid_cancer","/w/index.php?title=XL147&action=edit&redlink=1","/wiki/PI3K_inhibitor","/w/index.php?title=XL765&action=edit&redlink=1","/wiki/PI3K","/wiki/MTOR","/wiki/Foretinib","/wiki/XL518","/wiki/GDC0973","/wiki/MEK","/w/index.php?title=XL228&action=edit&redlink=1","/w/index.php?title=Insulin-like_growth_factor_type_1_receptor&action=edit&redlink=1","/w/index.php?title=XL139&action=edit&redlink=1","/wiki/CDC7","/w/index.php?title=XL888&action=edit&redlink=1","/wiki/HSP90","#cite_note-1","/wiki/XL184","/wiki/Medullary_thyroid_cancer","/wiki/Medullary_thyroid_cancer","/wiki/Orphan_drug","/wiki/Cabozantinib","/wiki/C-Met","/wiki/Kinase_insert_domain_receptor","/w/index.php?title=Exelixis&action=edit&section=1","/w/index.php?title=Exelixis&veaction=edit&section=1","#cite_ref-1","http://seekingalpha.com/article/270085-exelixis-looming-cancer-conference-a-favorable-swing-trade-opportunity","/w/index.php?title=Exelixis&action=edit&section=2","/w/index.php?title=Exelixis&veaction=edit&section=2","//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png","//commons.wikimedia.org/wiki/Category:Exelixis","http://www.exelixis.com","/wiki/File:Factory.svg","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Factory.svg/32px-Factory.svg.png","/wiki/Wikipedia:Stub","//en.wikipedia.org/w/index.php?title=Exelixis&action=edit","/wiki/Template:Med-company-stub","/wiki/Template_talk:Med-company-stub","//en.wikipedia.org/w/index.php?title=Template:Med-company-stub&action=edit","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","http://en.wikipedia.org/w/index.php?title=Exelixis&oldid=551777378","/wiki/Help:Category","/wiki/Category:Companies_listed_on_NASDAQ","/wiki/Category:Companies_in_the_NASDAQ_Biotechnology_Index","/wiki/Category:Biotechnology_companies_of_the_United_States","/wiki/Category:Medical_company_stubs","/wiki/Category:Commons_category_template_with_no_category_set","/wiki/Category:Commons_category_with_page_title_same_as_on_Wikidata","/w/index.php?title=Special:UserLogin&returnto=Exelixis&type=signup","/w/index.php?title=Special:UserLogin&returnto=Exelixis","/wiki/Exelixis","/wiki/Talk:Exelixis","#","/wiki/Exelixis","/w/index.php?title=Exelixis&action=edit","/w/index.php?title=Exelixis&veaction=edit","/w/index.php?title=Exelixis&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","//en.wikipedia.org/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Exelixis","/wiki/Special:RecentChangesLinked/Exelixis","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Exelixis&oldid=551777378","/w/index.php?title=Exelixis&action=info","//www.wikidata.org/wiki/Q5419989","/w/index.php?title=Special:Cite&page=Exelixis&id=551777378","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Exelixis","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Exelixis&oldid=551777378&writer=rl","/w/index.php?title=Exelixis&printable=yes","#","//www.wikidata.org/wiki/Q5419989#sitelinks-wikipedia","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//wikimediafoundation.org/wiki/Privacy_policy","//www.wikimediafoundation.org/","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//en.m.wikipedia.org/wiki/Exelixis","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":[],"pdf":[],"categories":["Companies listed on NASDAQ","Companies in the NASDAQ Biotechnology Index","Biotechnology companies of the United States"],"headings":["References","External links"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/1/19/Exilixis_logo.PNG/220px-Exilixis_logo.PNG","//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Factory.svg/32px-Factory.svg.png","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[],"members":[],"related":["Public_company","South_San_Francisco,_California","USA","Biotechnology","Genomics","Cometriq","Food_and_Drug_Administration","Medullary_thyroid_cancer","XL147","PI3K_inhibitor","XL765","PI3K","MTOR","Foretinib","XL518","GDC0973","MEK","XL228","Insulin-like_growth_factor_type_1_receptor","XL139","CDC7","XL888","HSP90","XL184","Medullary_thyroid_cancer","Medullary_thyroid_cancer","Orphan_drug","Cabozantinib","C-Met","Kinase_insert_domain_receptor"]}